NCT06596694

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment

Conditions

• Gastrointestinal Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Patritumab deruxtecan	Administered via intravenous (IV) infusion

Timeline

• Start date: 2024-11-03
• Primary completion: 2028-12-07
• Completion: 2028-12-07
• First posted: 2024-09-19
• Last updated: 2026-03-16

Locations

62 sites across 15 countries: United States, Australia, Canada, Chile, China, France, Israel, Italy, New Zealand, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey (Türkiye)

Regulatory

• FDA-regulated drug study